Tilray Inc. ($TLRY) Stock Forecast: Down 8.4% Today

What is Tilray Inc.?

Tilray Brands (TLRY) is a cannabis company facing stock market volatility linked to speculation on potential U.S. marijuana reform and federal rescheduling.

Why is Tilray Inc. going down?

TLRY stock is down 8.4% on Dec 19, 2025 20:41

• There was a significant bearish movement in TLRY stock today, possibly due to investors cashing out profits following a recent surge triggered by indications of potential marijuana reclassification by a former President.
• Market reaction may be influenced by experts warning that moving cannabis to Schedule III doesn't mean federal legalization, causing uncertainty and prompting selling.
• Despite forming Tilray Medical USA, Inc. to expand U.S. medical cannabis operations, the company's financial difficulties, ongoing losses, and focus on alcohol acquisitions rather than cannabis growth could be fueling negative market sentiment.
• The uncertain regulatory landscape for cannabis, paired with a recent reverse split and general market instability, may be intensifying downward pressure on Tilray's stock price.

TLRY Price Chart

TLRY Technical Analysis

TLRY News

Is Tilray Brands Stock a Buy, Sell, or Hold in 2026?

Tilray Brands stock is highly volatile and risky, with its performance heavily reliant on potential U.S. marijuana reform, specifically rescheduling rather than outright legalization. Despite recent optimism due to President Trump considering rescheduling, Tilray's Canadian base means rescheduling alone won't open the U.S. market for its marijuana products. The company's financial results are troubling, showing a net loss and cash burn, with growth primarily driven by acquisitions in the alcohol sector rather than its struggling cannabis segment.

https://www.fool.com/investing/2025/12/19/is-tilray-stock-a-buy-sell-or-hold-in-2026/

How a global cannabis provider is gearing up for a new era in U.S. care

Tilray Brands announced the formation of Tilray Medical USA, Inc. to advance its U.S. medical cannabis operations following federal rescheduling. The company plans to leverage its global experience, including over 200 registered medical cannabis products and participation in 15+ clinical studies, to lead innovation and growth in the evolving U.S. market. Tilray's CEO, Irwin D. Simon, highlighted the decision to reschedule cannabis as a significant catalyst for positive change and a critical step towards comprehensive regulation in the U.S.

https://www.stocktitan.net/news/TLRY/tilray-accelerates-u-s-medical-cannabis-expansion-after-landmark-4m58a2nokpgh.html

Tilray Brands (TLRY) Stock News Today: Trump Cannabis Rescheduling Reports Fuel Volatility, Fresh Forecasts and Key Levels (Dec. 17, 2025)

Tilray Brands (TLRY) stock experienced significant volatility on December 17, 2025, surging 27% amidst renewed speculation that President Donald Trump might issue an executive order to reclassify cannabis at the federal level to Schedule III. While this move could potentially reduce taxes, ease banking restrictions, and allow for more research, experts caution that it does not equate to federal legalization. The stock's recent 1-for-10 reverse split and the highly speculative nature of cannabis regulatory news are contributing to its large price swings, with option traders forecasting substantial moves by year-end and beyond.

https://ts2.tech/en/tilray-brands-tlry-stock-news-today-trump-cannabis-rescheduling-reports-fuel-volatility-fresh-forecasts-and-key-levels-dec-17-2025/

Pot stocks pop on Schedule 3 hopes: Tilray Brands, Trulieve Cannabis, Cresco Labs: How high will they go?

Shares of publicly traded cannabis companies, including Tilray Brands, Trulieve Cannabis, and Cresco Labs, are experiencing significant gains following reports that the Trump administration is considering reclassifying marijuana from a Schedule I to a Schedule III drug. While President Trump has indicated he is "considering" the reclassification to facilitate research, no official decision has been made. This potential change, which would lessen restrictions but not alter federal legality, has already led to impressive stock jumps for several major cannabis brands.

https://www.fastcompany.com/91461972/pot-stocks-price-rise-tilray-trulieve-cannabis-cresco-schedule-3-news

Stock Market Today, Dec. 16: Tilray Brands Surges 27.5% After Trump Signals Possible Marijuana Reclassification

Tilray Brands saw a significant 27.5% surge on December 16, 2025, following signals from former President Donald Trump regarding a possible reclassification of marijuana. This news led to a sector-wide cannabis rally, with other companies like Canopy Growth and Cronos Group also experiencing gains. The potential reclassification from a Schedule I to a Schedule III drug could expand the addressable market for cannabis producers like Tilray, allowing for medical use under federal law.

https://finance.yahoo.com/news/stock-market-today-dec-16-222038850.html

Trending Today

Ethereum ($ETH) Crypto Forecast: Up 5.6% Today

QTUM ($QTUM) Crypto Forecast: Up 6.2% Today

Unity Software ($U) Stock Forecast: Up 5.1% Today

Western Digital Corporation ($WDC) Stock Forecast: Up 5.3% Today

Oracle Corporation ($ORCL) Stock Forecast: Up 7.8% Today

Tilray Inc. ($TLRY) Stock Forecast: Down 8.4% Today

Norwegian Cruise Line Holdings Ltd. ($NCLH) Stock Forecast: Up 7.2% Today

Nike Inc. ($NKE) Stock Forecast: Down 11.7% Today

Monero ($XMR) Crypto Forecast: Up 5.3% Today

Lam Research Corporation ($LRCX) Stock Forecast: Up 5.1% Today

Tilray Inc. Price History

28.10.2025 - TLRY Stock was down 5.9%

• Tilray's stock took a hit today following the announcement of a 1-for-10 reverse stock split, which often signals a company's struggle to maintain its stock price.
• Despite posting strong Q1 cannabis growth and market share increases, the news of the reverse stock split overshadowed the positive performance, leading to a bearish trend.
• The market's reaction to the reverse stock split indicates investor concerns about Tilray's future prospects and financial health, contributing to the downward pressure on the stock price.
• Overall, the combination of the reverse stock split news and the market's response to it likely fueled the bearish movement in Tilray's stock today.

09.11.2025 - TLRY Stock was up 7.0%

• The launch of Tilray's Ultimate 2025 Holiday Drink Gift Guide featuring festive beverages may have sparked investor interest, hinting at potential expansion in the company's product range and consumer appeal.
• Following recent declines linked to internal changes, the stock saw a successful recovery, hitting a new 1-year peak, potentially influenced by heightened investor trust in Tilray's strategies and market position.
• Today's positive market outlook for Tilray could also be attributed to the overall industry optimism in the cannabis sector, with investors eyeing growth prospects in a sector shaped by changing consumer tastes and regulations.

19.11.2025 - TLRY Stock was down 8.4%

• There was a significant bearish movement in TLRY stock today, possibly due to investors cashing out profits following a recent surge triggered by indications of potential marijuana reclassification by a former President.
• Market reaction may be influenced by experts warning that moving cannabis to Schedule III doesn't mean federal legalization, causing uncertainty and prompting selling.
• Despite forming Tilray Medical USA, Inc. to expand U.S. medical cannabis operations, the company's financial difficulties, ongoing losses, and focus on alcohol acquisitions rather than cannabis growth could be fueling negative market sentiment.
• The uncertain regulatory landscape for cannabis, paired with a recent reverse split and general market instability, may be intensifying downward pressure on Tilray's stock price.

24.10.2025 - TLRY Stock was up 6.7%

• The introduction of Good Supply vape products in Québec by Tilray Brands could have sparked investor optimism and interest in the company's expansion into new markets, leading to increased buying activity and driving the stock price higher.
• The positive Q1 results and profitability momentum showcased by Tilray Brands indicate strong financial performance, which likely instilled confidence in investors and contributed to the bullish movement of the stock.
• The publication of a new investor presentation highlighting Tilray's leadership in various industries and its global growth strategy may have attracted new investors and bolstered existing shareholders' belief in the company's future prospects, potentially fueling the upward momentum in the stock price.

03.11.2025 - TLRY Stock was down 10.1%

• Tilray's stock has experienced a 24% drop over the past five sessions due to corporate restructuring and a reverse stock split.
• Negative company developments, including the reverse stock split and market pressures, have influenced the downward movement in TLRY's stock.
• Despite positive Q1 cannabis growth and a strengthened domestic position, the adverse effects of corporate changes have outweighed the positive news, leading to ongoing downward pressure on the stock.
• Investor response to Tilray's uncertainties and obstacles has caused the stock to decline further in line with broader market conditions.

16.11.2025 - TLRY Stock was up 5.8%

• TLRY experienced a substantial surge of 44.1% following potential discussions of a reclassification of marijuana at a federal level. This positive news not only impacted TLRY but also other cannabis stocks like Canopy Growth and Aurora Cannabis.
• The company's recent execution of a 10-for-1 reverse stock split, aimed at reducing its float and ensuring compliance with Nasdaq regulations, also influenced the bullish movement by boosting investor confidence.
• Surpassing its 200-day moving average and holding a Zacks Rank #3 (Hold) indicate a potential long-term bullish trend for TLRY, supported by positive earnings estimate revisions and strategic expansion into new markets.
• While the future looks promising, caution is advised due to the volatility in the cannabis sector. It is advisable for investors to closely monitor the situation until official confirmation and details regarding the potential policy change are disclosed.

17.11.2025 - TLRY Stock was down 8.1%

• Despite positive developments regarding the potential reclassification of marijuana from Schedule I to Schedule III, Tilray faced a bearish movement.
• The surge in Tilray's stock price post speculations on marijuana reclassification by Trump might have prompted profit-taking actions among investors, leading to the bearish movement.
• Uncertainty surrounding the final reclassification decision and profit-taking activities likely contributed to Tilray's stock price decline today.
• The market sentiment towards Tilray remains optimistic, anticipating future ease in federal restrictions and potential improvements in profitability.

17.11.2025 - TLRY Stock was up 16.2%

• TLRY stock surged by 44.1% due to speculation about a possible reclassification of marijuana as a Schedule III substance through an executive order.
• The surge in TLRY's stock price was driven by optimism about relaxed federal restrictions on cannabis and the potential business opportunities it could bring for companies in the industry.
• Despite the initial rally, the stock price cooled off as White House officials indicated that no final decision had been reached, showcasing the uncertainty surrounding the potential reclassification of marijuana. This led to profit-taking and a moderation in TLRY's price movement.
• Tilray's CEO emphasized the importance of clear regulation in the cannabis industry, especially regarding THC-infused drinks. He highlighted how regulatory clarity could benefit legitimate companies by ensuring quality standards and reducing illicit market activity.

12.11.2025 - TLRY Stock was up 31.7%

• The introduction of Redecan's Amped Live Resin Liquid Diamond 1g 510 cartridges in Canada has sparked enthusiasm and market interest, contributing to Tilray's upward movement.
• Positive developments related to the legalization of home marijuana cultivation in Florida and potential changes in federal cannabis regulations have bolstered investor confidence in Tilray's future outlook.
• Despite facing challenges such as increased expenses and a stock price decline, Tilray's expansion strategies and focus on evolving into a diversified consumer packaged goods (CPG) company have resonated well with traders and investors, driving the bullish market performance observed today.
• The company's adept handling of regulatory shifts and its ability to seize opportunities within the cannabis sector are expected to be key factors influencing its stock performance in the immediate future.

15.11.2025 - TLRY Stock was down 5.2%

• The bearish movement in TLRY today could be attributed to profit-taking by investors after a series of strong bullish movements.
• Despite the recent surge in TLRY's stock price, the lack of a definitive catalyst or news today may have led to a natural correction in the market.
• The mixed views from analysts regarding TLRY's future performance, balancing policy tailwinds with execution challenges, could have also contributed to the bearish movement as investors reassess the stock's potential.

10.11.2025 - TLRY Stock was up 12.0%

• Despite recent difficulties, Tilray (TLRY) witnessed a notable upward movement in the market today.
• This positive shift could be linked to the company's recent initiatives to expand into areas beyond its core cannabis business, such as broadening its beverage and hemp-derived THC product offerings.
• Investors seem hopeful about Tilray's potential for profitability despite ongoing losses, particularly with its focus on non-cannabis sectors to enhance profit margins.
• Today's optimistic market trend may also be driven by speculation regarding potential policy changes concerning the reclassification of cannabis, which could potentially benefit Tilray's future performance.

19.11.2025 - TLRY Stock was down 23.1%

• Today's bearish movement in TLRY may be due to investors taking profits following a recent surge influenced by discussions of President Trump contemplating cannabis reclassification.
• Though there is optimism about regulatory changes, the speculative nature of the cannabis industry and uncertainties regarding federal legalization may be causing some traders to proceed with caution.
• Volatility in TLRY's stock price could be impacted by option traders anticipating significant year-end movements, leading to short-term market fluctuations.
• It is important for investors to stay informed about any official announcements on cannabis regulations to navigate the current market volatility effectively.